FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296720483> ?p ?o ?g. }

• W4296720483 endingPage "e40811" @default.
• W4296720483 startingPage "e40811" @default.
• W4296720483 abstract "Background (Neo-)adjuvant chemotherapy for breast cancer is effective but has deleterious side effects on muscle tissue, resulting in reduced skeletal muscle mass, muscle function, and cardiorespiratory fitness. Various exercise regimens during cancer treatment have been shown to counteract some of these side effects. However, no study has compared the effect of high-intensity training versus low-to-moderate intensity training on muscle tissue cellular outcomes and physical function in patients with breast cancer during chemotherapy. Objective The aim of this substudy within the Physical Training in Cancer (Phys-Can) consortium is to evaluate and compare the effects of high and low-to-moderate intensity exercise on muscle cellular outcomes, muscle function, and cardiorespiratory fitness in women with breast cancer undergoing (neo-)adjuvant chemotherapy. We further aim to investigate if the effects of chemotherapy including taxanes on muscles will be different from those of taxane-free chemotherapy. Methods Eighty women recently diagnosed with breast cancer scheduled to start (neo-)adjuvant chemotherapy will be randomized to a combination of strength and endurance training, either at high intensity or at low-to-moderate intensity. Testing of muscle function and cardiorespiratory fitness and collection of muscle biopsies from the vastus lateralis muscle will be performed before the first cycle of chemotherapy (or after 1 week, when not possible) (T0), halfway through chemotherapy (T1), and after completion of chemotherapy (T2). It is estimated that approximately 50% of the participants will be willing to undergo muscle biopsies. To separate the effect of the treatment itself, a usual care group with no supervised training will also be included, and in this group, testing and collection of muscle biopsies will be performed at T0 and T2 only. Results This study is funded by Active Against Cancer (Aktiv mot kreft) (May 2013) and the Norwegian Cancer Society (December 2018). Inclusion started in December 2016 and the last participant is expected to be recruited in December 2022. As of June 2022, we enrolled 38 (19 with biopsies) participants to the high-intensity training group, 36 (19 with biopsies) participants to the low-to-moderate intensity training group, and 17 (16 with biopsies) participants to the usual care group. Data analyses will start in fall 2022. The first results are expected to be published in spring 2024. Conclusions This study will generate new knowledge about the effects of different training intensities for women with breast cancer during chemotherapy treatment. It will give further insight into how chemotherapy affects the muscle tissue and how physical training at different intensities may counteract the treatment side effects in muscles. The results of this study will inform the development and refinement of exercise programs that are effective and compatible with the multidisciplinary management of breast cancer. Trial Registration ClinicalTrials.gov NCT05218876; https://tinyurl.com/ysaj9dhm International Registered Report Identifier (IRRID) DERR1-10.2196/40811" @default.
• W4296720483 created "2022-09-23" @default.
• W4296720483 creator A5001219524 @default.
• W4296720483 creator A5034445725 @default.
• W4296720483 creator A5038808680 @default.
• W4296720483 creator A5044566282 @default.
• W4296720483 creator A5050515982 @default.
• W4296720483 creator A5083059837 @default.
• W4296720483 creator A5083087105 @default.
• W4296720483 creator A5086209931 @default.
• W4296720483 date "2022-11-11" @default.
• W4296720483 modified "2023-09-30" @default.
• W4296720483 title "Effects of High and Low-To-Moderate Intensity Exercise During (Neo-) Adjuvant Chemotherapy on Muscle Cells, Cardiorespiratory Fitness, and Muscle Function in Women With Breast Cancer: Protocol for a Randomized Controlled Trial" @default.
• W4296720483 cites W120288851 @default.
• W4296720483 cites W1847471344 @default.
• W4296720483 cites W1974297279 @default.
• W4296720483 cites W1978684156 @default.
• W4296720483 cites W1983641478 @default.
• W4296720483 cites W1988783251 @default.
• W4296720483 cites W2003239266 @default.
• W4296720483 cites W2013117898 @default.
• W4296720483 cites W2027096038 @default.
• W4296720483 cites W2032751700 @default.
• W4296720483 cites W2048929261 @default.
• W4296720483 cites W2064720249 @default.
• W4296720483 cites W2069189588 @default.
• W4296720483 cites W2096528587 @default.
• W4296720483 cites W2099879261 @default.
• W4296720483 cites W2100485228 @default.
• W4296720483 cites W2101046684 @default.
• W4296720483 cites W2122806520 @default.
• W4296720483 cites W2128000049 @default.
• W4296720483 cites W2132949875 @default.
• W4296720483 cites W2143341124 @default.
• W4296720483 cites W2152912882 @default.
• W4296720483 cites W2156420703 @default.
• W4296720483 cites W2166758089 @default.
• W4296720483 cites W2167571044 @default.
• W4296720483 cites W2295314306 @default.
• W4296720483 cites W2320909684 @default.
• W4296720483 cites W2598841605 @default.
• W4296720483 cites W2617892439 @default.
• W4296720483 cites W2734857932 @default.
• W4296720483 cites W2769880098 @default.
• W4296720483 cites W2774161211 @default.
• W4296720483 cites W2788867230 @default.
• W4296720483 cites W2801674502 @default.
• W4296720483 cites W2890169690 @default.
• W4296720483 cites W2914053210 @default.
• W4296720483 cites W2937092073 @default.
• W4296720483 cites W2942811334 @default.
• W4296720483 cites W2957186036 @default.
• W4296720483 cites W3127220211 @default.
• W4296720483 cites W3139161671 @default.
• W4296720483 cites W315805660 @default.
• W4296720483 cites W4237015088 @default.
• W4296720483 cites W4254315309 @default.
• W4296720483 cites W4319293029 @default.
• W4296720483 doi "https://doi.org/10.2196/40811" @default.
• W4296720483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36367769" @default.
• W4296720483 hasPublicationYear "2022" @default.
• W4296720483 type Work @default.
• W4296720483 citedByCount "1" @default.
• W4296720483 countsByYear W42967204832023 @default.
• W4296720483 crossrefType "journal-article" @default.
• W4296720483 hasAuthorship W4296720483A5001219524 @default.
• W4296720483 hasAuthorship W4296720483A5034445725 @default.
• W4296720483 hasAuthorship W4296720483A5038808680 @default.
• W4296720483 hasAuthorship W4296720483A5044566282 @default.
• W4296720483 hasAuthorship W4296720483A5050515982 @default.
• W4296720483 hasAuthorship W4296720483A5083059837 @default.
• W4296720483 hasAuthorship W4296720483A5083087105 @default.
• W4296720483 hasAuthorship W4296720483A5086209931 @default.
• W4296720483 hasBestOaLocation W42967204831 @default.
• W4296720483 hasConcept C117437137 @default.
• W4296720483 hasConcept C121608353 @default.
• W4296720483 hasConcept C126322002 @default.
• W4296720483 hasConcept C143998085 @default.
• W4296720483 hasConcept C168563851 @default.
• W4296720483 hasConcept C1862650 @default.
• W4296720483 hasConcept C2776694085 @default.
• W4296720483 hasConcept C530470458 @default.
• W4296720483 hasConcept C71924100 @default.
• W4296720483 hasConceptScore W4296720483C117437137 @default.
• W4296720483 hasConceptScore W4296720483C121608353 @default.
• W4296720483 hasConceptScore W4296720483C126322002 @default.
• W4296720483 hasConceptScore W4296720483C143998085 @default.
• W4296720483 hasConceptScore W4296720483C168563851 @default.
• W4296720483 hasConceptScore W4296720483C1862650 @default.
• W4296720483 hasConceptScore W4296720483C2776694085 @default.
• W4296720483 hasConceptScore W4296720483C530470458 @default.
• W4296720483 hasConceptScore W4296720483C71924100 @default.
• W4296720483 hasIssue "11" @default.
• W4296720483 hasLocation W42967204831 @default.
• W4296720483 hasLocation W42967204832 @default.
• W4296720483 hasLocation W42967204833 @default.
• W4296720483 hasLocation W42967204834 @default.
• W4296720483 hasOpenAccess W4296720483 @default.

• next